Figure 1. Association of Obesity With Survival and Radiographic Response in Patients Following Immune Checkpoint Blockade (ICB) Treatment.
All hazard ratios and 95% CIs were adjusted for tumor mutational burden, age, sex, tumor stage, drug class, neutrophil-to-lymphocyte ratio, ICB line of treatment, and Eastern Cooperative Oncology Group performance score with the Cox proportional-hazards regression model. For pancancer analyses, cancer type (melanoma, non–small cell lung cancer [NSCLC], and others) was adjusted. SCLC indicates small cell lung cancer. Radiographic response rates along with the 95% Wald CIs according to BMI groups across pancancer and 16 cancer types (D).